Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial

Giorgio Valabrega,Matthew A Powell,Sakari Hietanen,Eirwen M Miller,Zoltan Novak,Robert Holloway,Dominik Denschlag,Tashanna Myers,Anna M Thijs,Kathryn P Pennington,Lucy Gilbert,Evelyn Fleming,Oleksandr Zub,Lisa M Landrum,Beyhan Ataseven,Radhika Gogoi,Iwona Podzielinski,Noelle Cloven,Bradley J Monk,Sudarshan Sharma,Thomas J Herzog,Ashley Stuckey,Bhavana Pothuri,Angeles Alvarez Secord,Dana Chase,Veena Vincent,Oren Meyers,Jamie Garside,Mansoor Raza Mirza,Destin Black

doi:10.1136/ijgc-2024-005484

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial

Giorgio Valabrega, Matthew A Powell + Show 28 more

PDF Available

https://doi.org/10.1136/ijgc-2024-005484

Copy DOI

Export

Save

Cite

Journal: International Journal of Gynecologic Cancer

Publication Date: Sep 25, 2024

#Carboplatin Paclitaxel #Improvement In Progression Free Survival #Emotional Function #Quality Of Life Questionnaire Core #Recurrent Endometrial Cancer #Primary Endometrial Cancer #Advanced Endometrial Cancer #Patient-reported Outcomes #Improvements In Global Quality #Prespecified Exploratory Analysis

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

ObjectiveIn the ENGOT-EN6-NSGO/GOG3031/RUBY trial, dostarlimab+carboplatin–paclitaxel demonstrated significant improvement in progression free survival and a positive trend in overall survival compared with placebo+carboplatin–paclitaxel, with manageable toxicity, in patients with primary advanced...

Full Text

Paper version not known (Free)

View/Download pdf

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: International Journal of Gynecologic Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial